BioPharm > Trauma Recovery

Home / Psychoceuticals / Trauma Recovery

Trauma Recovery

A global wave of post-COVID mental health issues is predicted, including post traumatic stress disorder (PTSD), anxiety, depression, alcoholism and other addictions. BioPharm’s R&D team has expertise in psychotherapeutic agents ideal for the emerging models of intervention, and are currently developing new technology in this area.

Global wave of trauma

The COVID pandemic followed by economic recession has set conditions for a global wave of debillitating mental health and trauma related conditions such as depression, anxiety, PTSD, alcoholism and drug addiction, putting greater strain on health infrastructure. Several promising new technologies showing shorter recovery times and lower side effect profile than existing trauma treatments have been discovered, but more research is required. More effective therapies in this area will reduce strain on state health infrastructure. BioPharm’s R&D team have expertise in this area of natural and nature inspired molecules.

Psychopharmacological Areas

  • CBD derivatives showing anxyolytic activity.
  • Lysergamides.
  • Indole derivatives.
  • NMDA modulating molecules.
  • Empathogens.

Breakthrough Technologies

As understanding of the neuropharmacology of trauma grows, promising new treatments focusing on medically assisted psychotherapy are proving more effective than traditional models of symptomatic relief for trauma related mental health conditions such as PTSD, anxiety, depression, alcoholism and addiction. Globally, research is focusing on newer therapies involving single dose formulations, where previously patients were given long term medications to attenuate symptoms without addressing the root causes.

BioPharm is working in this exciting new area of medicinal development.

Want to know more about our research into trauma medicines?

× WhatsApp Chat